BioNTech SE (BioNTech SE) Investments And Advances : $1,283 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is BioNTech SE Investments And Advances?

BioNTech SE's Investments And Advances for the quarter that ended in Dec. 2023 was $1,283 Mil.

BioNTech SE's quarterly Investments And Advances declined from Jun. 2023 ($1,489 Mil) to Sep. 2023 ($1,380 Mil) and declined from Sep. 2023 ($1,380 Mil) to Dec. 2023 ($1,283 Mil).

BioNTech SE's annual Investments And Advances increased from Dec. 2021 ($24 Mil) to Dec. 2022 ($85 Mil) and increased from Dec. 2022 ($85 Mil) to Dec. 2023 ($1,283 Mil).

BioNTech SE Investments And Advances Historical Data

The historical data trend for BioNTech SE's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE Investments And Advances Chart

BioNTech SE Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Investments And Advances

Get a 7-Day Free Trial

24.07

84.96

1,282.55

BioNTech SE Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Investments And Advances	Get a 7-Day Free Trial															84.96	553.32	1,488.95	1,379.62	1,282.55

BioNTech SE Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.

BioNTech SE (BioNTech SE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (NAS:BNTX) » Definitions » Investments And Advances

Comparable Companies

Traded in Other Exchanges

BNTX:Mexico 0A3M:UK 22UA:Germany B1NT34:Brazil BNTX:Austria

Address

An der Goldgrube 12, Mainz, RP, DEU, D-55131

Website

https://www.biontech.de

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.